United States

People: Monsanto Co (MON.N)

MON.N on New York Stock Exchange

4:01pm EDT
Change (% chg)

$0.30 (+0.26%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Poste, George 

Dr. George H. Poste, Ph.D., D.V.M., is Independent Director of Monsanto Company. He is Chief Executive of Health Technology Networks, a consulting group specializing in the application of genomics technologies and computing in healthcare, since 1999; Chief Scientist, Complex Adaptive Systems Initiative, since 2009; Director of the Biodesign Institute, a combination of research groups at Arizona State University, 2003-2009; Chief Science and Technology Officer and Director, SmithKline Beecham, 1992-1999. Public Company Directorships in the Last Five Years: Exelixis, Inc. Dr. Poste is a scientist who has had extensive experience advising and leading research teams in both corporate and academic settings. He is a leader in synthetic biology and healthcare informatics, linking university research projects and collaborations. His roles as chief scientist leading research at a large university, and formerly as chief technology officer of a multi-national company, provide him valuable insight into the biotechnology industry and enable him to provide expert guidance, as chair of our science and technology committee, to our management and board as we develop and implement our technology strategies and research collaborations. In addition, his former roles on scientific advisory boards to the Federal government have also given him extensive experience related to risk management and regulatory and policy matters. His service as a director of other public companies, and as a member of the governance committee and chair of the research committees of other public companies, also bring valuable perspectives to our board.

Basic Compensation

Total Annual Compensation, USD 132,500
Restricted Stock Awards, USD 132,491
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 264,991

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Hugh Grant


Brett Begemann


Pierre Courduroux


Steven Mizell


Robert Fraley


David Snively

As Of  30 Aug 2016